194 related articles for article (PubMed ID: 28551309)
1. Ontak-like human IL-2 fusion toxin.
Wang Z; Zheng Q; Zhang H; Bronson RT; Madsen JC; Sachs DH; Huang CA; Wang Z
J Immunol Methods; 2017 Sep; 448():51-58. PubMed ID: 28551309
[TBL] [Abstract][Full Text] [Related]
2. Diphtheria toxin-based bivalent human IL-2 fusion toxin with improved efficacy for targeting human CD25(+) cells.
Peraino JS; Zhang H; Rajasekera PV; Wei M; Madsen JC; Sachs DH; Huang CA; Wang Z
J Immunol Methods; 2014 Mar; 405():57-66. PubMed ID: 24462799
[TBL] [Abstract][Full Text] [Related]
3. Development of a diphtheria toxin-based recombinant porcine IL-2 fusion toxin for depleting porcine CD25+ cells.
Peraino JS; Schenk M; Li G; Zhang H; Farkash EA; Sachs DH; Huang CA; Duran-Struuck R; Wang Z
J Immunol Methods; 2013 Dec; 398-399():33-43. PubMed ID: 24055128
[TBL] [Abstract][Full Text] [Related]
4. Bispecific human IL2-CCR4 immunotoxin targets human cutaneous T-cell lymphoma.
Wang H; Wang Z; Zhang H; Qi Z; Johnson AC; Mathes D; Pomfret EA; Rubin E; Huang CA; Wang Z
Mol Oncol; 2020 May; 14(5):991-1000. PubMed ID: 32107846
[TBL] [Abstract][Full Text] [Related]
5. Diphtheria toxin-based recombinant murine IL-2 fusion toxin for depleting murine regulatory T cells in vivo.
Wei M; Marino J; Trowell A; Zhang H; Stromp Peraino J; Rajasekera PV; Madsen JC; Sachs DH; Huang CA; Benichou G; Wang Z
Protein Eng Des Sel; 2014 Sep; 27(9):289-95. PubMed ID: 25147093
[TBL] [Abstract][Full Text] [Related]
6. A truncated diphtheria toxin based recombinant porcine CTLA-4 fusion toxin.
Peraino JS; Schenk M; Zhang H; Li G; Hermanrud CE; Neville DM; Sachs DH; Huang CA; Duran-Struuck R; Wang Z
J Immunol Methods; 2013 May; 391(1-2):103-11. PubMed ID: 23470981
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
Foss FM
Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
[TBL] [Abstract][Full Text] [Related]
8. Diphtheria-toxin based anti-human CCR4 immunotoxin for targeting human CCR4(+) cells in vivo.
Wang Z; Wei M; Zhang H; Chen H; Germana S; Huang CA; Madsen JC; Sachs DH; Wang Z
Mol Oncol; 2015 Aug; 9(7):1458-70. PubMed ID: 25958791
[TBL] [Abstract][Full Text] [Related]
9. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
[TBL] [Abstract][Full Text] [Related]
10. Diphtheria toxin-based anti-human CD19 immunotoxin for targeting human CD19
Zheng Q; Wang Z; Zhang H; Huang Q; Madsen JC; Sachs DH; Huang CA; Wang Z
Mol Oncol; 2017 May; 11(5):584-594. PubMed ID: 28306193
[TBL] [Abstract][Full Text] [Related]
11. Denileukin diftitox.
Figgitt DP; Lamb HM; Goa KL
Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
[TBL] [Abstract][Full Text] [Related]
12. The IL-2 diphtheria toxin fusion protein denileukin diftitox modulates the onset of diabetes in female nonobese diabetic animals in a time-dependent manner and breaks tolerance in male nonobese diabetic animals.
Zinser E; Rössner S; Littmann L; Pangratz N; Schuler G; Steinkasserer A
J Immunol; 2012 Aug; 189(3):1173-81. PubMed ID: 22730534
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapies: Denileukin diftitox--a step towards a 'magic bullet' for CTCL.
Kadin ME; Vonderheid EC
Nat Rev Clin Oncol; 2010 Aug; 7(8):430-2. PubMed ID: 20668480
[No Abstract] [Full Text] [Related]
14. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
15. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
Duvic M; Kuzel TM; Olsen EA; Martin AG; Foss FM; Kim YH; Heald PW; Bacha P; Nichols J; Liepa A
Clin Lymphoma; 2002 Mar; 2(4):222-8. PubMed ID: 11970761
[TBL] [Abstract][Full Text] [Related]
16. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro.
Mahnke K; Schönfeld K; Fondel S; Ring S; Karakhanova S; Wiedemeyer K; Bedke T; Johnson TS; Storn V; Schallenberg S; Enk AH
Int J Cancer; 2007 Jun; 120(12):2723-33. PubMed ID: 17315189
[TBL] [Abstract][Full Text] [Related]
17. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
[TBL] [Abstract][Full Text] [Related]
18. Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case.
Kerl K; Prins C; Cerroni L; French LE
Br J Dermatol; 2006 May; 154(5):988-91. PubMed ID: 16634908
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with denileukin diftitox (ONTAK).
Foss F
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S11-6. PubMed ID: 16516670
[TBL] [Abstract][Full Text] [Related]
20. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication.
Foss FM; Bacha P; Osann KE; Demierre MF; Bell T; Kuzel T
Clin Lymphoma; 2001 Mar; 1(4):298-302. PubMed ID: 11707845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
